TNFRSF17 and cancer: Finally, the specificity of the BCMA-targeting CAR to the BCMA was demonstrated by the significant decrease in IFN-γ production when adding the soluble recombinant BCMA-Fc protein to counteract the BCMA-specific CAR recognition of RPMI-8226 cancer cells (Figure 2E).